Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (RETRO CRVO)

Bayer

Status: Completed

Conditions: Retinal Vein Occlusion

Treatments: Drug: Aflibercept (Eylea, BAY86-5321)

Study type: Observational

Funder types: Industry

Identifiers

NCT02645747

18586

Details and patient eligibility

About

The objective of this retrospective chart review is to evaluate drug utilization, usage patterns and indication of effectiveness Eylea in the routine clinical (real-life) management of patients who suffer from ME (Macular Edema), secondary to CRVO (Central Retinal Vein Occlusion), and who started treatment with Eylea for this indication.

Enrollment: 126 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female adult patients who suffer from visual impairment due to ME secondary to CRVO
• Anti-VEGF treatment-naive patients who started reimbursed Eylea treatment between the 1st of June 2014 and the 28th of February 2015

Exclusion criteria

• Patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.

Trial design

126 participants in 1 patient group

Group 1

Description:

The source population of this study is patients who suffer from visual impairment due to ME secondary to CRVO. In order to ensure the representativeness of the study population, the number of Belgian patients which started Eylea treatment during the brief period between the 1st of June 2014 and the 28th of February 2015 were taken into account. However, data of patients diagnosed with neovascular glaucoma secondary to CRVO will be excluded.

Treatment:

Drug: Aflibercept (Eylea, BAY86-5321)